Dataset Information

MetaboLights MTBLS360 - GNPS Metabolomics and lipidomics reveal perturbation of sphingolipid metabolism by a novel anti-trypanosomal 3-(oxazolo[4,5-b]pyridine-2-yl)anilide

ABSTRACT: This data set was downloaded from MetaboLights (http://www.ebi.ac.uk/metabolights/) accession number MTBLS360 Abstract:Trypanosoma brucei is the causative agent of human African trypanosomiasis, which is responsible for thousands of deaths every year. Current therapies are limited and there is an urgent need to develop new drugs. The anti-trypanosomal compound, 3-(oxazolo[4,5-b]pyridine-2-yl)anilide (OXPA), was initially identified in a phenotypic screen and subsequently optimized by structure–activity directed medicinal chemistry. It has been shown to be non-toxic and to be active against a number of trypanosomatid parasites. However, nothing is known about its mechanism of action.

INSTRUMENT(S): Exactive (Thermo Scientific)

ORGANISM(S): Blank

SUBMITTER: Creek

PROVIDER: MSV000082775 | GNPS | Tue Aug 07 10:25:00 BST 2018

REPOSITORIES: GNPS

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Although 80% of AML patients can initially achieve a complete remission, the long-term disease-free survival is only 40% at 6 years with a 10% 5-year survival rate from first relapse. Most patients do not achieve a second remission. Therefore, relapse after initial response to chemotherapy remains a serious clinical challenge requiring new therapeutic strategies. Annual relapse rates have been calculated 40%, 17%, and 2% in years 1-3, respectively. One of the issues hindering the successful treatment of AML patients, and contributing to disease relapse, is leukaemic cell adhesion and retention in the protective niche of the BMME. Here, the leukaemic cells are surrounded by other cell types that promote their survival, by enabling them to evade destruction by both the immune system and intra-vascular therapies, ultimately leading to the emergence of drug resistance. Given the dependence of AML cells on the BMME, a better understanding of the biological interactions between the leukaemic cells and the haematopoietic niche is needed. In addition, the identification and development of therapies to target these adhesive interactions will enable AML cells to be forced out of their BMME protective niche, into the peripheral circulation, where they will be more susceptible to conventional drug regimens. We have developed and optimised a robust, reproducible, in vitro co-culture model of the AML-BMME. Using the optimised model, several adhesion blocking agents were tested to reduce the number of adhered AML cells. Anti-CD44 treatment was established as the most effective in preventing AML adhesion of OCI-AML3, KG1a and primary AML cells. However, even with maximum dose of the most promising blocking agent, some AML cells still adhered. Following this observation, KG1a and OCI-AML3 cells were treated in co-culture and monoculture. Subsequently paired adhered, non-adhered and monoculture cells were isolated and sent for RNA sequencing in order to perform comparative transcriptomic analysis. The results from these experiments helped us identify novel targets from the persistently adhered AML cells in order to more effectively block their adhesion on our model.

Dataset Information

MetaboLights MTBLS360 - GNPS Metabolomics and lipidomics reveal perturbation of sphingolipid metabolism by a novel anti-trypanosomal 3-(oxazolo[4,5-b]pyridine-2-yl)anilide

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets